With the ongoing obesity epidemic 1,2 and the emergence of promising new pharmacologic agents for obesity such as GLP-1 agonists, 3 providers may be increasingly called upon to consider incorporating weight-loss pharmacotherapy into clinical practice
By analyzing body composition changes (fat vs
For example, two 6mg injections instead of one 12mg injection can smooth the concentration curve and reduce nausea peaks
Beyond their well-established benefits in managing type 2 diabetes mellitus (T2DM) and promoting weight reduction, emerging evidence suggests that GLP-1 RAs may also offer neuroprotective, anti-inflammatory, and cardiovascular protective effects 4,5,6,7
The modeling of TM16-TM17 allows the identification of putative residues for the stimulated transport of GSH The above results led us to conclude that among the expressed chimeras, M8 is the most significantly affected both for inducing CS and for its GSH-dependent transport activity